Table 3 Prognostic factors of overall survival and progression-free survival based upon univariate analysis presented as hazard ratios with 95% confidence intervals.

Rituximab (yes vs no)

1.51 (0.7–3.2)

0.28

Sex (male vs female)

1.1 (0.7–1.8)

0.66

Lymphoma stage

I, II vs III, IV

3.1 (1.5–6.4)

0.003

Age (as a categorical value)

(>50 and ≤60) vs <50

>60 vs <50

1.2 (0.6–2.3)

2.1 (1.2–3.6)

0.57

0.01

IPI

1–2 vs 3–5

2.5 (1.4–4.3)

0.001

Type 2 diabetes mellitus

1.9 (1.2–3.2)

0.01

Pre-existing HF

2.5 (1.4–4.4)

0.002

Hypertension

1 (0.6–1.6)

0.95

Lipid abnormalities

0.8 (0.4–1.6)

0.44

Obesity

0.9 (0.5–1.6)

0.76

Smoking

1.1 (0.6–1.9)

0.69

Rituximab (yes vs no)

0.85 (0.5–1.4)

0.53

Sex (male vs female)

1.25 (0.9–1.8)

0.23

Lymphoma stage

I, II vs III, IV

2.5 (1.5–4.3)

<0.001

Age (as a categorical value)

(>50 and ≤60) vs <50

>60 vs <50

1.0 (0.6–1.6)

1.3 (0.9–2.0)

1.0

0.16

IPI

1–2 vs 3–5

2.7 (1.8–4.1)

<0.001

Type 2 diabetes mellitus

1.6 (1.03–2.4)

0.036

Pre-existing HF

1.9 (1.1–3.1)

0.014

Hypertension

1.0 (0.7–1.5)

0.83

Lipid abnormalities

0.9 (0.5–1.7)

0.77

Obesity

0.8 (0.5–1.3)

0.43

Smoking

1.3 (0.8–1.9)

0.28